175 related articles for article (PubMed ID: 30237815)
1. EROS study: evaluation between high-dose-rate and low-dose-rate vaginal interventional radiotherapy (brachytherapy) in terms of overall survival and rate of stenosis.
Autorino R; Tagliaferri L; Campitelli M; Smaniotto D; Nardangeli A; Mattiucci GC; Macchia G; Gui B; Miccò M; Mascilini F; Ferrandina G; Kovacs G; Valentini V; Gambacorta MA
J Contemp Brachytherapy; 2018 Aug; 10(4):315-320. PubMed ID: 30237815
[TBL] [Abstract][Full Text] [Related]
2. American Brachytherapy Society survey regarding practice patterns of postoperative irradiation for endometrial cancer: current status of vaginal brachytherapy.
Small W; Erickson B; Kwakwa F
Int J Radiat Oncol Biol Phys; 2005 Dec; 63(5):1502-7. PubMed ID: 16109462
[TBL] [Abstract][Full Text] [Related]
3. Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial.
Nout RA; Smit VT; Putter H; Jürgenliemk-Schulz IM; Jobsen JJ; Lutgens LC; van der Steen-Banasik EM; Mens JW; Slot A; Kroese MC; van Bunningen BN; Ansink AC; van Putten WL; Creutzberg CL;
Lancet; 2010 Mar; 375(9717):816-23. PubMed ID: 20206777
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant Chemotherapy and Vaginal Vault Brachytherapy With or Without Pelvic Radiotherapy for Stage 1 Papillary Serous or Clear Cell Endometrial Cancer.
Tétreault-Laflamme A; Nguyen-Huynh TV; Carrier JF; Samouëlian V; Sauthier P; Beauchemin MC; Barkati M
Int J Gynecol Cancer; 2016 Feb; 26(2):301-6. PubMed ID: 26745699
[TBL] [Abstract][Full Text] [Related]
5. Combined brachytherapy and ultra-hypofractionated radiotherapy for intermediate-risk prostate cancer: Comparison of toxicity outcomes using a high-dose-rate (HDR) versus low-dose-rate (LDR) brachytherapy boost.
Kollmeier MA; Gorovets D; Flynn J; McBride S; Brennan V; Beaudry J; Cohen G; Damato A; Zhang Z; Zelefsky MJ
Brachytherapy; 2022; 21(5):599-604. PubMed ID: 35725549
[TBL] [Abstract][Full Text] [Related]
6. Late G2 vagina toxicity in post-operative endometrial carcinoma is associated with a 68 Gy dose equivalent to 2 Gy per fraction
Aguilera MDV; Rovirosa Á; Ascaso C; Herreros A; Sánchez J; Garcia-Migue J; Cortes S; Agusti E; Camacho C; Zhang Y; Li Y; Sabater S; Torne A; Arenas M
J Contemp Brachytherapy; 2018 Feb; 10(1):40-46. PubMed ID: 29619055
[TBL] [Abstract][Full Text] [Related]
7. Overview of adjuvant radiotherapy on survival, failure pattern and toxicity in stage I to II endometrial carcinoma: a long-term multi-institutional analysis in China.
Wang W; Wang T; Liu Z; He J; Sun X; Zhong W; Zhao F; Li X; Li S; Zhu H; Ma Z; Hu K; Zhang F; Hou X; Wei L; Zou L
BMC Cancer; 2022 Mar; 22(1):266. PubMed ID: 35287626
[TBL] [Abstract][Full Text] [Related]
8. High-dose-rate brachytherapy monotherapy versus low-dose-rate brachytherapy with or without external beam radiotherapy for clinically localized prostate cancer.
Yamazaki H; Masui K; Suzuki G; Nakamura S; Yamada K; Okihara K; Shiraishi T; Yoshida K; Kotsuma T; Tanaka E; Otani K; Yoshioka Y; Ogawa K
Radiother Oncol; 2019 Mar; 132():162-170. PubMed ID: 30416045
[TBL] [Abstract][Full Text] [Related]
9. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
[TBL] [Abstract][Full Text] [Related]
10. Low-/high-dose-rate brachytherapy boost in patients with intermediate-risk prostate cancer treated with radiotherapy: long-term results from a single institution team experience.
Villalba SR; Denia PM; Pérez-Calatayud MJ; Sancho JR; Pérez-Calatayud J; Escrivá AF; Tendero PT; Ortega MS
J Contemp Brachytherapy; 2021 Apr; 13(2):135-144. PubMed ID: 33897786
[TBL] [Abstract][Full Text] [Related]
11. Effective treatment of stage I uterine papillary serous carcinoma with high dose-rate vaginal apex radiation (192Ir) and chemotherapy.
Turner BC; Knisely JP; Kacinski BM; Haffty BG; Gumbs AA; Roberts KB; Frank AH; Peschel RE; Rutherford TJ; Edraki B; Kohorn EI; Chambers SK; Schwartz PE; Wilson LD
Int J Radiat Oncol Biol Phys; 1998 Jan; 40(1):77-84. PubMed ID: 9422561
[TBL] [Abstract][Full Text] [Related]
12. Preliminary results of a vaginal constraint for reducing G2 late vaginal complications after postoperative brachytherapy in endometrial cancer: a prospective analysis.
Zhang Y; Gomez G; Ascaso C; Herreros A; Fornes B; Mases J; Rochera J; Tagliaferri L; Sabater S; Torne A; Biete A; Rovirosa Á
Clin Transl Oncol; 2022 May; 24(5):875-881. PubMed ID: 34854030
[TBL] [Abstract][Full Text] [Related]
13. High versus low dose rate intracavitary irradiation for adenocarcinoma of the uterine cervix.
Kim WC; Kim GE; Suh CO; Loh JJ
Jpn J Clin Oncol; 2001 Sep; 31(9):432-7. PubMed ID: 11689597
[TBL] [Abstract][Full Text] [Related]
14. A comparative analysis of overall survival between high-dose-rate and low-dose-rate brachytherapy boosts for unfavorable-risk prostate cancer.
King MT; Yang DD; Muralidhar V; Mahal B; Butler S; Devlin PM; Lee LJ; Mouw KW; Martin NM; D'Amico AV; Nguyen PL; Orio PF
Brachytherapy; 2019; 18(2):186-191. PubMed ID: 30638912
[TBL] [Abstract][Full Text] [Related]
15. Comparison of acute and late toxicities for three modern high-dose radiation treatment techniques for localized prostate cancer.
Mohammed N; Kestin L; Ghilezan M; Krauss D; Vicini F; Brabbins D; Gustafson G; Ye H; Martinez A
Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):204-12. PubMed ID: 21167653
[TBL] [Abstract][Full Text] [Related]
16. High-dose-rate versus low-dose-rate brachytherapy in the treatment of cervical cancer: analysis of tumor recurrence--the University of Wisconsin experience.
Petereit DG; Sarkaria JN; Potter DM; Schink JC
Int J Radiat Oncol Biol Phys; 1999 Dec; 45(5):1267-74. PubMed ID: 10613322
[TBL] [Abstract][Full Text] [Related]
17. EROS 2.0 study: evaluation of two interventional radiotherapy (brachytherapy) schedules for endometrial cancer: a comparison of late vaginal toxicity rates.
Lancellotta V; Macchia G; Dinapoli N; Autorino R; Campitelli M; Nardangeli A; Salvati A; Fionda B; Casà C; Cornacchione P; Rovirosa A; Kovács G; Morganti AG; Ferrandina MG; Gambacorta MA; Tagliaferri L
Radiol Med; 2022 Mar; 127(3):341-348. PubMed ID: 35092552
[TBL] [Abstract][Full Text] [Related]
18. Impact of High-Dose-Rate and Low-Dose-Rate Brachytherapy Boost on Toxicity, Functional and Cancer Outcomes in Patients Receiving External Beam Radiation Therapy for Prostate Cancer: A National Population-Based Study.
Parry MG; Nossiter J; Sujenthiran A; Cowling TE; Patel RN; Morris M; Berry B; Cathcart P; Clarke NW; Payne H; van der Meulen J; Aggarwal A
Int J Radiat Oncol Biol Phys; 2021 Apr; 109(5):1219-1229. PubMed ID: 33279595
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant radiotherapy for stage I endometrial cancer.
Kong A; Johnson N; Kitchener HC; Lawrie TA
Cochrane Database Syst Rev; 2012 Mar; (3):CD003916. PubMed ID: 22419290
[TBL] [Abstract][Full Text] [Related]
20. Practice patterns of adjuvant radiotherapy in women with stage I to II endometrial carcinoma: a real-world multi-institutional analysis in China.
Wang W; Wang T; Liu Z; He J; Sun X; Zhong W; Zhao F; Li X; Li S; Zhu H; Ma Z; Hu K; Zhang F; Hou X; Wei L; Zou L
BMC Womens Health; 2023 Aug; 23(1):417. PubMed ID: 37553639
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]